相关实验视频

Updated: May 7, 2026

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

15.9K

间歇性与持续的卡路里限制相比,用于治疗与代谢功能障碍相关的脂肪性肝病:一项随机临床试验

Xiaoyang Sun1, Fan Li2, Hongmei Yan1

  • 1Department of Endocrinology, Zhongshan Hospital, Fudan University, Shanghai, China; Institute of Metabolic Disease, Fudan University, Shanghai, China.

The American journal of clinical nutrition
|October 24, 2024
PubMed
概括

间歇性卡路里限制 (ICR) 和持续性卡路里限制 (CCR) 在MASLD患者中同样降低了肝脂肪. ICR 5:2饮食为MASLD治疗提供了可行的替代方案,并显示出高度的坚持.

关键词:
持续的卡路里限制.间歇性的卡路里限制.肝脏脂肪含量 肝脏脂肪含量与代谢功能障碍相关的脂肪性肝病.

更多相关视频

Assessment of the Metabolic Effects of Isocaloric 2:1 Intermittent Fasting in Mice08:06

Assessment of the Metabolic Effects of Isocaloric 2:1 Intermittent Fasting in Mice

Published on: November 27, 2019

8.9K
Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss07:03

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

792

相关概念视频

Metabolic States of the Body: Fasting and Starvation01:24

Metabolic States of the Body: Fasting and Starvation

During the initial hours of fasting, the body uses up its glycogen stores as an energy source. Once these glycogen reserves are depleted, the body begins breaking down stored triglycerides and structural proteins. During this stage, glycerol becomes a key substrate for gluconeogenesis, while free fatty acids undergo beta-oxidation to provide energy for tissues, such as skeletal muscle. In the fasting state, the body spares protein breakdown as much as possible to conserve muscle and structural...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...